

PROGRAM

Twenty Fourth Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders

Presented by the Parkinson Study Group, Huntington Study Group, Dystonia Study Group, Myoclonus Study Group, Tourette Syndrome Study Group, Cooperative Ataxia Group, and Tremor Research Group

To be held on Saturday, 15 May 2010, in the Four Seasons Ballroom at the Four Seasons Resort, Irving, Texas, 8:30 a.m. to 5:00 p.m.

The symposium will consist of current issues in genetic and environmental contributions to Parkinson's disease and other movement disorders with peer-reviewed platform and poster presentations designed to communicate recent research advances, including new pharmacological and non-pharmacological treatment options, in the field of Parkinson's disease, Huntington's disease, ataxia, dystonia, myoclonus, Tourette's syndrome, tremor and other movement disorders thereby enhancing patient care.

Current Issues in Genetic and Environmental Contributions to Parkinson's Disease and Other Movement Disorders. This morning session is in honor of the late Clifford W. Shults, MD and hosted by the PSG Genetics and Environmental Risk Working Group.

8:30-8:35 AM

Introduction and acknowledgements by Connie Marras, MD, Chair, PSG Genetics and Environmental Risk Working Group. The following presentations are 20 minutes followed by 10 minutes questions and answers by the audience. The panel discussions are 35 minutes long with 10 minutes for questions and answers by the audience.

8:35-8:55 AM

PRESENTATION: Approaches to Gene Discovery.

David K. Simon, MD, PhD. *Associate Professor of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.*

9:05-9:25 AM

PRESENTATION: The Spectrum of Genetic Contributions to Parkinson's Disease.

Martha Nance, MD. *Adjunct Professor of Neurology at the University of Minnesota, Medical Director of the Struthers Parkinson's Center and Director of the Hennepin County Medical Center HD Center of Excellence, St. Louis Park, MN, USA.*

9:35-9:55 AM

Panel Discussion: Melanoma and PD: Association and implications for practice.

Panel Presentation: Epidemiology of melanoma and PD and implications for pathophysiology.

Xiang Gao, MD, PhD. *Research Scientist, Harvard School of Public Health, Instructor in Medicine, Harvard Medical School, Associate Epidemiologist, Brigham and Women's Hospital, Boston, MA, USA.*

Panel Presentation: Melanoma and PD: Summary of findings from surveillance studies.

Anthony Lang, MD. *Professor of Neurology and Senior Scientist, Division of Patient Based Clinical Research, Toronto Western Research Institute, Toronto, Ontario, Canada.*

Panel Presentation: Implications for practice – should we be making recommendations for screening and what should they be?

Karl Kieburtz MD, MPH. *Director, Center for Human Experimental Therapeutics, Professor of Neurology, Preventative Medicine, and Environmental Medicine, Rochester, NY, USA.*

10:05-10:20 AM BREAK

10:20-10:50 AM

PRESENTATION: Update on Environmental Contributions to Parkinson's Disease and Other Movement Disorders.

Alberto Ascherio, MD, PhD. *Professor of Epidemiology and Nutrition, Harvard School of Public Health and Professor of Medicine at the Harvard Medical School, Boston, MA, USA.*

11:00-11:35 AM

PANEL DISCUSSION: Recommendations for Collection, Storage and Use of Genetic and Environmental Data in Parkinson's Disease Clinical Trials.

Introductory remarks by Lin Zhang, MD, PhD, Co-chair, PSG Genetics and Environmental Risk Working Group.

Panel Presentation: Genetic Data Collection: Recommendations, Rationale.

Tatiana Foroud, PhD. *P. Michael Conneally Professor of Medicine and Molecular Genetics at Indiana University School of Medicine, Indianapolis, IN, USA.*

Panel Presentation: Environmental Data Collection: Current Initiatives, Recommendations, Rationale.

Caroline Tanner, MD, PhD. *Director of Clinical Research, The Parkinson's Institute, Sunnyvale, CA, USA.*

Panel Presentation: Considerations of Subject Burden, Implications of Genetic Testing to Subjects.

Christine Hunter, RN, CCRC. *Instructor of Neurology, Baylor College of Medicine, Houston, TX, USA.*

Presentations on Parkinson's Disease and Other Movement Disorders. This afternoon session is hosted by the PSG Symposium Organizing Committee. This session consists of a poster session, a guest speaker presentation for 25 minutes with 5 minutes allotted time for questions and answers and 6 platform presentations for 10 minutes with 5 minutes allotted time for questions and answers by the audience.

11:45 AM-12:00 PM

Review and Highlights of Posters by Andrew Feigin, MD, Co-chair, PSG Symposium Organizing Committee.

12:00-1:00 PM

POSTER SESSION: This session consists of presentation of posters by the presenting authors with audience participation.

1:00-1:30 PM

GUEST SPEAKER PRESENTATION: Genetics of Ataxia.

Christopher M. Gomez, MD, PhD, *Professor and Chair, Department of Neurology, University of Chicago.*

1:30-1:45 PM

Serum Cholesterol as a Predictor of the Rate of Clinical Decline in Parkinson Disease: Results from DATATOP.

Xuemei Huang,¹ Peggy Auinger,² Shirley Eberly,³ David Oakes,³ Michael Schwarzschild,⁴ Alberto Ascherio,⁵ Richard Mailman,⁶ Honglei Chen,⁷ for the Parkinson Study Group DATATOP Investigators. ¹*Departments of Neurology, Neurosurgery, Pharmacology, Radiology, Kinesiology, and Bioengineering, Pennsylvania State University-Milton Hershey Medical Center, Hershey, PA;* ²*Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, New York;* ³*Department of Biostatistics, University of Rochester, Rochester, NY;* ⁴*Department of Neurology, Massachusetts General Hospital, Boston, MA;* ⁵*School of Medical Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA;* ⁶*Departments of Neurology, Pharmacology, Pennsylvania State University-Milton Hershey Medical Center, Hershey, PA;* ⁷*Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.*

1:45-2:00 PM

Prevalence and Comorbidity of Psychiatric Diagnoses in a Community-based Sample of Patients with Parkinson's Disease (PD).

L. Marsh,^{1,2} E.S. Hirsch,² K.E. Anderson,³ SA Goldstein,^{2,4} S. Grill,² S. Lehmann,² J.T. Little,^{2,5} R.L. Margolis,² J. Palanci,² G.M. Pontone,² P.V. Rabins,² H.W. Weiss,² J.R. Williams.^{4,6} ¹*Baylor College of Medicine/ Michael E. DeBakey Veterans Affairs Medical Center, (current affiliation);* ²*Johns Hopkins University School of Medicine, USA;* ³*University of Maryland School of Medicine,* ⁴*Food and Drug Administration, (current affiliation);* ⁵*Georgetown University School of Medicine, (current affiliation);* ⁶*Johns Hopkins Bloomberg School of Public Health, USA.*

2:00-2:15 PM

Psychogenic Symptoms in Patients with Huntington's Disease.

K.M. Shannon,¹ J. Jaglin.¹ ¹Rush University Medical Center, Chicago, IL, USA.

2:15-2:30 PM BREAK

2:30-2:45 PM

Antidepressant Treatment May Have Disease Modifying-effects in Early Parkinson's Disease: A Patient-level Meta-analysis.

K.L. Paumier,¹ A.D. Siderowf,² P. Auinger,³ D. Oakes,³ A.J. Espay,⁴ F.J. Revilla,⁴ A. Sahay,⁴ and T.J. Collier,¹ for the Parkinson Study Group Genetics and Environmental Risk Working Group. ¹Department of Neurology, University of Cincinnati, Cincinnati, Ohio; ²Department of Psychiatry, University of Pennsylvania, Philadelphia; ³University of Rochester School of Medicine and Dentistry, Rochester, New York; ⁴The Neuroscience Institute, Department of Neurology, Movement Disorders Center, University of Cincinnati, Cincinnati, OH, USA.

2:45-3:00 PM

LATE-BREAKING RESEARCH

Using Telemedicine to Conduct New Patient Evaluations for Individuals with Movement Disorders.

L.M. Deuel,¹ N.J. Scoglio,¹ J.I. Reminick,^{2,3} B.P. George,² B. Rajan,³ A. Joseph,⁴ A. Seidmann,³ E.R. Dorsey,¹ K.M. Biglan.¹ ¹Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York; ²University of Rochester School of Medicine and Dentistry, Rochester, New York; ³Simon School of Business, University of Rochester, Rochester, New York; ⁴Presbyterian Home for Central New York, Inc., New Hartford, New York, USA.

3:00-3:15 PM

LATE-BREAKING RESEARCH

Dopamine Transporter (DAT) Imaging Predicts Motor and Treatment-Resistant Outcomes in Parkinson Disease.

K Marek,¹ B. Ravina,² J. Seibyl,¹ D. Jennings,¹ S. Eberly,² D. Oakes,² I. Shoulson,² for the PSG PostCEPT (LABS-PD) Investigators. ¹Institute for Neurodegenerative Disorders, New Haven, CT; ²University of Rochester, Rochester, NY, USA.

3:15-3:30 PM

AWARDS PRESENTATION: Presentation of best abstract awards by the PSG Symposium Committee.

3:30-5:00 PM

Additional time for viewing of posters and exhibits.

POSTER SESSION

POSTER 1

Late-onset Neurological Wilson's Disease without K-F Rings or Characteristic MRI Findings.

E. S. Molho. Albany Medical College, Albany, New York, USA.

POSTER 2

The Effect of Onabotulinumtoxin (Botox®) Treatment on Restless Legs Syndrome.

P. Agarwal,¹ C. Sia,² N.K. Vaish.³ ¹Booth Gardner Parkinson's Center, Kirkland, WA and University of Washington, ²Booth Gardner Parkinson's Center, Kirkland, WA; ³ Biotechnology company, Bothell, WA, USA.

POSTER 3

Brain Magnetic Resonance Imaging in Atypical Parkinsonism.

R. Malkani,¹ A. Videnovic,¹ C. Zadikoff,¹ T. Simuni,¹ M. Walker.¹ ¹Northwestern University, Chicago, IL, USA.

POSTER 4

Differences in Motor and Cognitive Function in Patients with Parkinsonism with and without Orthostatic Hypotension.

T. Ellis,^{1,3} A.D. Hohler,^{2,3} D. I. Katz,^{2,3} T. J. DePiero,^{2,3} C. L. Hehl,³ A. Leonard,³ V. Allen,³ J. Dentino,³ M. Gardner,³ H. Phenix,³ M.H. Saint-Hilaire.^{1,2} ¹*Boston University: College of Health & Rehabilitation Sciences: Sargent;* ²*Boston University School of Medicine;* ³*Braintree Rehabilitation Hospital, USA.*

POSTER 5

Utility of the NeuroTrax Computerized Battery for Cognitive Screening in Parkinson's Disease: Comparison to the MMSE and MoCA.

B. Hanna-Pladdy,^{1,2} A. Enslein,^{1,3} M. Fray,^{1,3} B.J. Gajewski,⁴ R. Pahwa,³ K.E. Lyons.³ ¹*Landon Center on Aging,* ²*Department of Psychiatry & Behavioral Sciences, University of Kansas Medical Center, Kansas City, KS;* ³*Parkinson's Disease and Movement Disorders Center, Department of Neurology, University of Kansas Medical Center, Kansas City, KS;* ⁴*Department of Biostatistics, School of Nursing, University of Kansas Medical Center, Kansas City, KS, USA.*

POSTER 6

Clinical Validation of Diagnostic Procedures for Parkinson's Disease Dementia (PD-D).

B. R. Barton,¹ D. Grabli,² B. Bernard,¹ V. Czernecki,² J. Goldman,¹ G. Stebbins,¹ B. Dubois,² C. G. Goetz.¹ ¹*Rush University Medical Center, USA;* ²*Hôpital de la Salpêtrière, Paris, France.*

POSTER 7

Effects of Acute Medication Challenge on Quantitative Measures in Standard Movement Tests in Parkinson Disease.

X.K.Gao, K.A.Bonnet. *Eastern Neurologic Services, New York, NY, USA.*

POSTER 8

The Washington State Parkinson Disease Registry.

J.B. Leverenz,^{1,3,4,5,6} H.M. Kim,^{1,5} A. Samii,^{1,4,5} B. Gerton,^{1,5} M. Baca,¹ J. Pate,¹ E. Martinez,¹ S. Thomas,¹ D.W. Tsuang,^{1,3,6} C.P. Zabetian.^{1,2,4,5} ¹*VA-Puget Sound Health Care System,* ²*Geriatric,* ³*Mental Illness, and* ⁴*Parkinson Disease Research, Education, and Clinical Centers. Departments of* ⁵*Neurology and Psychiatry and* ⁶*Behavioral Sciences, University of Washington, Seattle, WA, USA.*

POSTER 9

Vascular Diseases and Cerebral Angiopathy in Patients with Parkinson's Disease and Parkinsonian Syndrome.

R. A. Norman. *Silesian Medical University, Katowice, Poland.*

POSTER 10

Accumulation of Co-morbidities Worsens Functional Mobility and Motor Deficits in Persons with PD.

K.B. Foreman,¹ J.T. Cavanaugh,² G.M. Earhart,³ T.D. Ellis,⁴ M.P. Ford,⁵ L.E. Dibble.¹ ¹*University of Utah, Salt Lake City, UT;* ²*University of New England, Portland, ME;* ³*Washington University, St Louis, MO;* ⁴*Boston University, Boston, MA;* ⁵*University of Alabama at Birmingham, Birmingham, AL, USA.*

POSTER 11

Perisaccadic Gamma Lateralization with Voluntary Saccades in Parkinson Disease and Controls.

M.A. Javaid,¹ S. Glazman,¹ I. Bodis-Wollner.¹ ¹*SUNY Downstate Med Center, Brooklyn, NY, USA.*

POSTER 12

Early Clinical Predictors of Treatment-Resistant Outcomes in Parkinson Disease.

R. Kurlan,¹ B. Ravina,² S. Eberly,² D. Oakes,² I. Shoulson,² for the PSG PostCEPT (LABS-PD) Investigators. ¹*Atlantic Neuroscience Institute, Overlook Hospital, Summit, NJ;* ²*University of Rochester, Rochester, NY, USA.*

POSTER 13

Genetic Polymorphisms of the Cholecystokinin (CCK) System in Parkinson's Disease Patients with and without Hallucinations.

J.G. Goldman,¹ D. Marr,² L. Zhou,¹ B. Ouyang,¹ S.E. Leurgans,¹ E. Berry-Kravis,¹ C. G. Goetz.¹ ¹Rush University Medical Center, Chicago, IL, USA; ²University of British Columbia, Canada.

POSTER 14

Significance and Confounders of Peripheral DJ-1 and α -synuclein in Parkinson Disease.

M. Shi,¹ C.P. Zabetian,¹ K.A. Chung,² J.F. Quinn,² E.R. Peskind,¹ D. Galasko,³ J. Jankovic,⁴ J.B. Leverenz,¹ and J. Zhang.¹ ¹University of Washington, Seattle, WA; ²Oregon Health and Science University, Portland, OR; ³University of California, San Diego, CA; ⁴Baylor College Medicine, Houston, TX, USA.

POSTER 15

NIC-PD - A Randomized, Placebo-controlled, Double-blind, Multi-centre Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Drug-naïve, Early Parkinson's Disease in Germany and the USA.

M. M. Unger,¹ J. C. Möller,¹ K. Kiebertz,² W. H. Oertel.¹ ¹Philipps-University Marburg, Department of Neurology, Marburg, Germany; ²University of Rochester, Department of Neurology, Rochester, USA.

POSTER 16

Hereditary Parkinson's Disease of Unknown Genetic Cause in Two Families from Southern Sweden.

A.J. Puschmann,^{1,2,3} S. Lindskov,⁴ C. Marktorp,⁴ C. Nilsson,^{2,3} K. Nilsson,^{2,3} J. Reimer,^{2,3} D. van Westen,² E. Persson,² H. Widner,² S. Lincoln,¹ S. Cobb,¹ O. Ross,¹ C. Vilarinho-Güell,¹ M. Farrer,¹ Z.K. Wszolek.¹ ¹Mayo Clinic Jacksonville, USA; ²Lund University, Sweden; ³Swedish Parkinson Academy, Sweden; ⁴Central Hospital Kristianstad, Sweden.

POSTER 17

Let's Dance! Gait and QOL after Dance Therapy in PD.

L.M. Daniel, E.A. Murray, C.H. Jung, J. Millar, E. Talles, S.R. Dunlop, D. Solomon, R. von Coelln, Z. Mari, and S.H. Ying. Johns Hopkins University, Baltimore, MD, USA.

POSTER 18

Quantitative Electroencephalography as a Predictor for Parkinson's Disease Dementia.

B. Klassen,¹ J. Hentz,¹ C.H. Adler,¹ H. Shill,² E. Driver-Dunckley,¹ V. Evidente,¹ M. Sabbagh,² J. N. Caviness.¹ ¹Mayo Clinic, Scottsdale, Arizona; ²Sun Health Research Institute, Banner Health System, Sun City, Arizona, USA.